The COVID-19 pandemic has devastated economic and public health, and healthcare industry has been busy developing the vaccines, antivirals, and supportive treatments which is a time-consuming process in order to develop drugs and get approval.
Unlike other industries, COVID-19 pandemic has further created opportunities for the biotechnology companies to utilise the opportunity and showcase the capabilities of computer aided drug design and development.
Increasing cost of drug development and lack of new chemical entities are the growing concerns for new development of drugs. COVID-19 is providing greater opportunities for drug repurposing activities and companies are increasingly using computer aided drug discovery to study the existing drug effects on COVID-19.
There have been major developments in In-Silico Drug repurposing across the world, where they develop new use to an old existing drug, which is a cost effective strategy to develop drug for COVID-19.
With the outbreak of SARS-CoV-2 virus causing the COVID-19 pandemic, and researchers are turning towards computer simulations and AI technologies to identify potential treatments.
For instance, in June 2020, Delta 4, a biotech company has applied its drug discovery platform to identify and shortlisting potential COVID-19 drug using computer models
Increasing laboratories, researchers and drug development organisations are using of AI(artificial Intelligence), quantum mechanical scoring, and other computer simulation and genomic analysis methodologies.
For instance, In June 2020, Ennaid Therapeutics are developing antiviral drugs for COVID-19 using AI-based drug discovery platforms. ENU200, a repurposed orally deliverable antiviral drug is able to treat up to 80% of asymptomatic, mild to moderate cases of COVID-19 viral infections. The company yet to avail approvals for use in COVID-19.